NasdaqCM - Nasdaq Real Time Price USD
Jasper Therapeutics, Inc. (JSPR)
6.01
+0.31
+(5.44%)
At close: June 6 at 4:00:01 PM EDT
5.80
-0.21
(-3.49%)
After hours: June 6 at 7:17:59 PM EDT
Insider Purchases Last 6 Months
| Shares | Transactions | |
|---|---|---|
| Purchases | 900 | 1 |
| Sales | 900 | 1 |
| Net Shares Purchased (Sold) | 0 | 2 |
| Total Insider Shares Held | 190.33k | -- |
| % Net Shares Purchased (Sold) | 0.00% | -- |
Net Institutional Purchases Prior Quarter to Latest Quarter
| Shares | |
|---|---|
| Net Shares Purchased (Sold) | -- |
| % Change in Institutional Shares Held | -- |
Insider Transactions Reported - Last Two Years
| Insider | Transaction | Type | Value | Date |
|---|---|---|---|---|
| MAHAL JEETINDER SINGH Chief Operating Officer | Sale at price 22.11 per share. | Direct | 19,899 | Dec 12, 2024 |
| MAHAL JEETINDER SINGH Chief Operating Officer | Conversion of Exercise of derivative security at price 7.10 per share. | Direct | 6,390 | Dec 12, 2024 |
| MAHAL JEETINDER SINGH Chief Operating Officer | Sale at price 21.23 per share. | Direct | 19,104 | Sep 12, 2024 |
| MAHAL JEETINDER SINGH Chief Operating Officer | Conversion of Exercise of derivative security at price 7.10 per share. | Direct | 6,390 | Sep 12, 2024 |
| MAHAL JEETINDER SINGH Chief Operating Officer | Sale at price 24.16 per share. | Direct | 21,740 | Jun 12, 2024 |
| MAHAL JEETINDER SINGH Chief Operating Officer | Conversion of Exercise of derivative security at price 7.10 per share. | Direct | 6,390 | Jun 12, 2024 |
| TUCKER EDWIN JONATHAN Officer | Stock Award(Grant) at price 24.52 per share. | Direct | 9,808 | Jun 7, 2024 |
| MAHAL JEETINDER SINGH Chief Operating Officer | Sale at price 26.44 per share. | Direct | 23,792 | Mar 12, 2024 |
| MAHAL JEETINDER SINGH Chief Operating Officer | Conversion of Exercise of derivative security at price 7.10 per share. | Direct | 6,390 | Mar 12, 2024 |
| CARLYLE GROUP, INC. Unknown | Purchase at price 17.36 per share. | Indirect | 3,298,400 | Feb 8, 2024 |
| VELAN CAPITAL INVESTMENT MANAGEMENT LP Beneficial Owner of more than 10% of a Class of Security | Purchase at price 17.36 per share. | Indirect | 6,076,000 | Feb 8, 2024 |
| WIGGANS THOMAS G Director | Purchase at price 0.65 per share. | Direct | 6,486 | Nov 28, 2023 |
| WIGGANS THOMAS G Director | Purchase at price 0.64 per share. | Direct | 6,383 | Nov 21, 2023 |
| WIGGANS THOMAS G Director | Purchase at price 0.60 - 0.63 per share. | Direct | 18,240 | Nov 20, 2023 |
| LIS WILLIAM DAVID Director | Sale at price 0.85 per share. | Direct | 6,777 | Oct 13, 2023 |
| MAHAL JEETINDER SINGH Chief Operating Officer | Sale at price 1.66 per share. | Direct | 14,915 | Jun 13, 2023 |
| MAHAL JEETINDER SINGH Chief Operating Officer | Conversion of Exercise of derivative security at price 0.71 per share. | Direct | 6,390 | Jun 13, 2023 |
Related Tickers
LRMR Larimar Therapeutics, Inc.
2.6800
+8.94%
IMRX Immuneering Corporation
2.1300
+3.90%
TRVI Trevi Therapeutics, Inc.
7.06
+4.75%
CLDX Celldex Therapeutics, Inc.
21.35
+9.32%
ANAB AnaptysBio, Inc.
23.70
+12.11%
IMTX Immatics N.V.
5.97
+3.29%
LXEO Lexeo Therapeutics, Inc.
3.8800
+18.65%
NKTR Nektar Therapeutics
0.6660
-1.30%
AUTL Autolus Therapeutics plc
2.3400
+3.54%
CGEM Cullinan Therapeutics, Inc.
9.08
+3.89%